Cabozantinib plus atezolizumab significantly improved progression-free survival (PFS) versus androgen receptor pathway inhibitor (ARPI) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) and extrapelvic soft-tissue metastases.
No statistically significant improvement in overall survival (OS) was observed with the combination therapy compared to ARPI switch.
The combination regimen was associated with a higher incidence of grade 3–4 adverse events, but no new safety signals emerged.
This study identifies a novel, non-AR-targeted therapeutic option for a difficult-to-treat mCRPC population.
